Denes Korpas, MD
Interventional Cardiology · Lincoln, NENPI 1902992399
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $7,095 of the $9,445 with a category attached, or 75.1%. 33 manufacturers reported payments, led by Boston Scientific at 29.8% of the total.
Across 329 payments — averaging $28.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$3K
- Medtronic$3K
- Impulse Dynamics (USA) Inc.$799
- Novartis$512
- E.r. Squibb & Sons, L.L.C.$412
- Sanofi-aventis U.S. LLC$292
- plus $2K from 27 others
Across 50 payments — averaging $2942.93 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$72K
- Amgen$53K
- Esperion Therapeutics, Inc.$22K
What the payments were for
- Travel & lodging$2,33825%
- Food & beverage$7,09575%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 59 | $2,814 |
| Medtronic(2 entities) | 33 | $2,507 |
| Impulse Dynamics (USA) Inc. | 23 | $799 |
| Novartis | 39 | $512 |
| E.r. Squibb & Sons, L.L.C. | 32 | $412 |
| Sanofi-aventis U.S. LLC | 19 | $292 |
| Amgen | 17 | $237 |
| Pfizer | 15 | $207 |
| Esperion Therapeutics, Inc. | 7 | $204 |
| Johnson & Johnson | 10 | $144 |
| Boehringer Ingelheim | 9 | $132 |
| Novo Nordisk | 8 | $129 |
| Heartflow, Inc. | 5 | $124 |
| Merck | 7 | $113 |
| Itamar Medical Inc | 2 | $104 |
| Abbott | 4 | $86 |
| Edwards Lifesciences | 3 | $63 |
| Chiesi USA, Inc. | 3 | $58 |
| Lexicon Pharmaceuticals, Inc. | 4 | $56 |
| AstraZeneca | 4 | $52 |
| Amarin Pharma, Inc. | 4 | $50 |
| Regeneron Healthcare Solutions, Inc. | 3 | $50 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 5 | $46 |
| Baxter Healthcare | 2 | $46 |
| Teleflex LLC | 2 | $40 |
| Philips North America LLC | 1 | $29 |
| Actelion Pharmaceuticals US, Inc. | 2 | $28 |
| Bridgebio Pharma, Inc. | 1 | $27 |
| Bayer | 2 | $27 |
| Biotronik Inc. | 1 | $22 |
| Gilead | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
| Lundbeck LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL - THERAPIES$1,274
- OPTIMIZER$498
- AZURE XT DR MRI SURESCAN$307
- COREVALVE EVOLUT R$251
- Evera$125
- NEXLIZET$125
- NEXLETOL$125
- LUX-Dx Insertable Cardiac Monitor$107
How this compares
$9,445 in reported general payments places this provider in the 60th percentile of 50 interventional cardiology providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 331 | $283,531 |
| XareltoRivaroxaban | 219 | $210,439 |
| CamzyosMavacamten | 22 | $184,490 |
| EntrestoSacubitril/Valsartan | 124 | $108,232 |
| Repatha SureclickEvolocumab | 119 | $83,926 |
| NortheraDroxidopa | 13 | $71,517 |
| Praluent PenAlirocumab | 67 | $42,925 |
| FarxigaDapagliflozin Propanediol | 18 | $25,124 |
| JardianceEmpagliflozin | 27 | $22,333 |
| BrilintaTicagrelor | 38 | $18,524 |
| Droxidopa | 15 | $11,955 |
| Ranolazine ErRanolazine | 117 | $8,728 |
| Flecainide Acetate | 202 | $8,099 |
| Nebivolol Hcl | 137 | $7,492 |
| LivaloPitavastatin Calcium | 17 | $7,439 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $207 | $283,531331 claims |
| Johnson & JohnsonXarelto | $144 | $210,439219 claims |
| E.r. Squibb & Sons, L.L.C.Camzyos | $412 | $184,49022 claims |
| NovartisEntresto | $512 | $108,232124 claims |
| Lundbeck LLCNorthera | $11 | $71,51713 claims |
| AstraZenecaFarxiga, Brilinta | $52 | $43,64856 claims |
| Boehringer IngelheimJardiance | $132 | $22,33327 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $12 | $7,43917 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 50 interventional cardiology providers in Nebraska.
Other interventional cardiology in Lincoln
- Brock CookmanLincoln$782K
- Matthew JohnsonLincoln$162K
- Steven MartinLincoln$55K
- Natraj KattaLincoln$18K
- Hemantha KoduriLincoln$10K
- Harpaul BajwaLincoln$7K
- Zachary SingsankLincoln$4K
- Douglas NetzLincoln$3K
- Vishwajeth BhoopalamLincoln$3K
- Melissa AlvarezLincoln$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.